Provider briefing: Victoza supply in 2026

The ongoing shortage of GLP-1 receptor agonists has created significant challenges for clinicians managing patients with type 2 diabetes. Victoza (Liraglutide), a once-daily injectable GLP-1 RA manufactured by Novo Nordisk, remains subject to intermittent supply disruptions as of early 2026.

This article provides an evidence-informed overview of the current shortage landscape, prescribing considerations, and practical tools to support your patients and clinical workflow.

Shortage timeline and current status

The GLP-1 supply crisis began accelerating in 2022–2023, driven primarily by unprecedented demand for Semaglutide-based products (Ozempic, Wegovy). Victoza, while less affected initially, has seen increasing supply pressure as:

• Patients unable to obtain Semaglutide products have been switched to Liraglutide
• Overall GLP-1 prescribing volumes have continued to rise year-over-year
• Novo Nordisk has prioritized manufacturing capacity for higher-margin products
• Off-label weight management prescribing has expanded demand beyond the diabetes population

As of Q1 2026, Victoza is listed in intermittent shortage status. Supply varies significantly by region, distributor, and pharmacy type.

Prescribing implications

The shortage introduces several clinical considerations:

Continuity of care

Patients who have been stable on Victoza may face gaps in therapy if their pharmacy cannot fill the prescription. Abrupt discontinuation can lead to hyperglycemic episodes, particularly in patients relying on Liraglutide as a primary glucose-lowering agent.

Therapeutic substitution

When Victoza is unavailable, intra-class switching to another GLP-1 RA is the most clinically appropriate approach. Key substitution options include:

• Semaglutide (Ozempic) — once-weekly injection; strong cardiovascular and glycemic data; also subject to supply constraints
• Dulaglutide (Trulicity) — once-weekly injection; generally more available; comparable efficacy
• Tirzepatide (Mounjaro) — once-weekly dual GIP/GLP-1 RA; superior A1C and weight reduction in head-to-head trials; may require prior authorization
• Oral Semaglutide (Rybelsus) — once-daily oral option; suitable for injection-averse patients; requires fasting administration
• Exenatide (Byetta/Bydureon) — older GLP-1 RA options; less commonly used but may have better availability

For a patient-facing overview of these alternatives, see Alternatives to Victoza.

Prior authorization considerations

Switching agents may trigger new prior authorization requirements. Consider proactively submitting PAs for alternative GLP-1 agents so patients have a backup option if Victoza becomes unavailable.

Availability and distribution patterns

Clinical experience and pharmacy reports suggest:

• Independent pharmacies may have access to different wholesaler allocations than chain pharmacies
• Specialty pharmacies focused on injectable medications may carry deeper Victoza inventory
• Regional variation is significant — metropolitan areas may see better supply than rural regions
• Restock cycles typically occur 2–3 times per week at most pharmacies

Cost and access barriers

Victoza's list price remains approximately $1,000–$1,300 per month without insurance coverage. For patients facing cost barriers:

• Novo Nordisk NovoCare Savings Card: Commercially insured patients may pay as low as $25/month
• Novo Nordisk Patient Assistance Program (PAP): Provides free medication to qualifying uninsured patients
• Discount platforms: GoodRx, SingleCare, and similar services may reduce out-of-pocket costs for cash-pay patients

Detailed cost-saving strategies for patients are available at How to save money on Victoza in 2026.

Tools for real-time stock verification

Rather than having staff call multiple pharmacies, providers can direct patients — or use themselves — real-time medication availability tools:

• Medfinder for Providers — real-time Victoza stock checking by zip code, designed for clinical workflows
• Direct outreach to specialty pharmacies and compounding pharmacies with GLP-1 RA inventory

Integrating a stock-check step into your prescribing workflow can reduce patient callbacks and failed fills.

Looking ahead

Several developments may affect Victoza availability in the coming months:

• Manufacturing expansion: Novo Nordisk has committed significant capital expenditure to increase GLP-1 production capacity, though full impact may not be seen until late 2026 or 2027.
• Biosimilar/generic pipeline: While no generic Liraglutide is currently available in the U.S., the patent landscape is evolving and follow-on products may eventually enter the market.
• Evolving guidelines: As newer dual-agonist therapies (e.g., Tirzepatide) gain broader formulary placement, some prescribing may shift away from Liraglutide, potentially easing supply pressure.

Final thoughts

The Victoza shortage requires proactive management from prescribers. Key strategies include maintaining backup prescriptions for alternative GLP-1 agents, pre-emptive prior authorization submissions, and leveraging tools like Medfinder to verify real-time pharmacy availability.

For a practical guide on supporting patients through the shortage, see How to help your patients find Victoza in stock.